Am­gen kicks back I/O drug at cen­ter of $500M deal, leav­ing biotech part­ner alone to pon­der next steps

Just ahead of a planned Phase I read­out, Am­gen is punt­ing back an im­muno-on­col­o­gy drug to Mol­e­c­u­lar Part­ners.

Am­gen cit­ed a “strate­gic pipeline re­view” for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER